Published in PLoS One on May 22, 2014
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients (2015) 0.87
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res (2015) 0.84
Experimental models of liver fibrosis. Arch Toxicol (2015) 0.78
Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play. World J Gastroenterol (2016) 0.77
Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int (2015) 0.76
Transient Hepatic Overexpression of Insulin-Like Growth Factor 2 Induces Free Cholesterol and Lipid Droplet Formation. Front Physiol (2016) 0.75
Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol (2016) 0.75
Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. Sci Rep (2017) 0.75
Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int J Exp Pathol (2017) 0.75
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Liver regeneration. Hepatology (2006) 7.52
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52
alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One (2010) 2.94
Animal models of steatosis. Semin Liver Dis (2001) 2.88
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia (2005) 2.67
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology (2010) 2.48
Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med (2008) 2.39
Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology (2010) 2.30
Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci (2009) 2.29
From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis (2010) 2.24
Sterile inflammation in the liver. Gastroenterology (2012) 2.17
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int (2011) 2.14
Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09
Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo. Mol Cell Biol (2007) 2.08
Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology (2014) 1.86
Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology (2013) 1.80
IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev (2008) 1.73
Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol (2010) 1.67
Inflammasomes in liver diseases. J Hepatol (2012) 1.67
Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes (2012) 1.63
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology (2009) 1.59
NASH and HCC. Clin Liver Dis (2009) 1.52
Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology (2005) 1.50
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer (2007) 1.30
Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes (2001) 1.24
Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res (2002) 1.20
Predominant role of gluconeogenesis in the hepatic glycogen repletion of diabetic rats. J Clin Invest (1992) 1.14
A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol (2012) 1.08
Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract (2011) 1.06
PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol (2008) 1.05
In vivo effects of glucosamine on insulin secretion and insulin sensitivity in the rat: possible relevance to the maladaptive responses to chronic hyperglycaemia. Diabetologia (1995) 1.00
PTEN in liver diseases and cancer. World J Gastroenterol (2010) 0.97
From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights. Curr Pharm Des (2013) 0.96
Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res (2010) 0.89
Endoplasmic Reticulum stress induces hepatic stellate cell apoptosis and contributes to fibrosis resolution. Liver Int (2012) 0.88
Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care (2013) 0.88
Estrogens maintain bile duct mass and reduce apoptosis after biliodigestive anastomosis in bile duct ligated rats. J Hepatol (2005) 0.83
Epoxyeicosatrienoic acids and heme oxygenase-1 interaction attenuates diabetes and metabolic syndrome complications. Prostaglandins Other Lipid Mediat (2011) 0.83